These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8222296)

  • 1. Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects.
    García-Mayor RV; Pérez AJ; Gandara A; Andrade A; Mallo F; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):337-43. PubMed ID: 8222296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D; Schaefer F; Girard J; Ritz E; Mehls O
    J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in growth hormone secretion and clearance in peripubertal boys with chronic renal failure and after renal transplantation. Cooperative Study Group of Pubertal development in Chronic Renal Failure.
    Schaefer F; Veldhuis JD; Stanhope R; Jones J; Schärer K
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1298-306. PubMed ID: 8200929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin.
    Hindmarsh PC; Matthews DR; Brain CE; Pringle PJ; di Silvio L; Kurtz AB; Brook CG
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):443-50. PubMed ID: 2574646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin-dependent) diabetes mellitus.
    Mullis PE; Pal BR; Matthews DR; Hindmarsh PC; Phillips PE; Dunger DB
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):255-63. PubMed ID: 1348664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency.
    Catalina PF; Páramo C; Andrade MA; Mallo F
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):341-7. PubMed ID: 17302866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients.
    Díez JJ; Iglesias P; Aguilera A; Bajo MA; Selgas R
    Nephrol Dial Transplant; 1999 Jul; 14(7):1704-9. PubMed ID: 10435880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects.
    Valcavi R; Zini M
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):379-82. PubMed ID: 8187302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects.
    Sohmiya M; Kato Y
    J Clin Endocrinol Metab; 1992 Dec; 75(6):1487-90. PubMed ID: 1464653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered GH elimination kinetics in type 1 diabetes mellitus can explain the elevation in circulating levels: bicompartmental approach.
    Catalina PF; Andrade MA; García-Mayor RV; Mallo F
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1785-90. PubMed ID: 11932318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M; Günther T; von zur Mühlen A; Brabant G
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D; Popovic V; Kendereski A; Peino R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease.
    Tönshoff B; Veldhuis JD; Heinrich U; Mehls O
    Pediatr Res; 1995 Jan; 37(1):86-93. PubMed ID: 7700739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ; Iglesias P; Selgas R; Bajo MA; Aguilera A
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men.
    Shah N; Aloi J; Evans WS; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2862-9. PubMed ID: 10443692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones.
    Skamene A; Patel YC
    Clin Endocrinol (Oxf); 1984 May; 20(5):555-64. PubMed ID: 6146413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma.
    Schaefer F; Baumann G; Haffner D; Faunt LM; Johnson ML; Mercado M; Ritz E; Mehls O; Veldhuis JD
    J Clin Endocrinol Metab; 1996 Jan; 81(1):22-31. PubMed ID: 8550755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of growth hormone (GH) plasma clearance rate, half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion.
    Lanzi R; Andreotti AC; Caumo A; Manzoni MF; Losa M; Malighetti ME; Pontiroli AE
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3279-83. PubMed ID: 7593438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disappearance half-life times of exogenous and growth hormone-releasing factor-stimulated endogenous growth hormone in normal rats.
    Chapman IM; Helfgott A; Willoughby JO
    J Endocrinol; 1991 Mar; 128(3):369-74. PubMed ID: 2013743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.